Mechanistic studies of IL-17 versus TNF blockade in Spondyloarthritis

Objectives of the Project

SpA is a multi-faceted inflammatory disease previously classified according to the major phenotypic features. In this project, we hypothesize that blockade of IL-17A and TNF affects different pathophysiological pathways, resulting in distinct biological and ultimately clinical outcomes. We aim to identify specific biological effects by systematic translational comparison of IL-17A versus TNF blockade in SpA patients using combined molecular, cellular and imaging approaches.

Read more

Facts and Figures

Project Lead
Dr. N Yeremenko
AMC Amsterdam
FOREUM research grant: € 300.000
2016 - 2019

Meet the Team

Dr. N Yeremenko
AMC Amsterdam
Dr. A Hueber
University Hospital Erlangen
Prof. C Miceli
Institut Pasteur Paris
Dr. L Rogge
Institut Pasteur Paris
Dr. C van der Laken
VU Medisch Centrum, Stichting VUmc
Mr. van der Zalm
Stichting Bechterew in Beweging
Mrs. L Salij
Stichting Bechterew in Beweging

Patient Voice

Patients and patient organizations will be involved at two crucial stages of the project. First, they will actively contribute to promote recruitment.

Second, a lay advisory board of patients will be instrumental in the interpretation of the data, in particular in addressing the question if and how the anticipated biologic profiles can be applied in a useful way to stratify individual patients or patient groups to anti-TNF versus anti-IL17A treatment.


  • Eleni Kampylafka, Isabelle d’Oliveira, Christina Linz, Veronika Lerchen, Fabian Stemmler, David Simon, Matthias Englbrecht, Michael Sticherling, Jürgen Rech, Arnd Kleyer, Georg Schett, Axel J. Hueber. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018 Jul 27;20(1):153. doi: 10.1186/s13075-018-1653-5
    Read publication